avacopan · Chemocentryx · NDA 214487
Tavneos
Earliest generic entry, as listed
27 Nov 2039
Blocked by patent: US 11603356, US 11951214.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11603356 | substance, product, use U-3558 | 27 Nov 2039 |
| US 11951214 | product | 27 Nov 2039 |
| US 8906938 | substance, product | 6 Jan 2034 |
| US 8445515 | substance, product | 3 Feb 2031 |
Exclusivities · 1 unexpired
| ODE-377 | orphan drug (7 years) | 7 Oct 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 214487 · 001 · RLD | capsule, oral | 10MG | 27 Nov 2039 |
Expired or delisted (1)
- NCE · 7 Oct 2026